3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Leukemia, Myeloid, Acute
6
Breast Neoplasms
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Mesothelioma, Malignant
3
Lymphoma, Non-Hodgkin
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Pleural Effusion, Malignant
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid
2
Leukemia
2
Head and Neck Neoplasms
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Merkel Cell
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Interventions
pembrolizumab
25
Paclitaxel
20
Carboplatin
17
Bevacizumab
12
Specimen Handling
10
Letrozole
10
abemaciclib
7
dostarlimab
6
Taxes
6
Blood Specimen Collection
6
Medroxyprogesterone Acetate
5
Magnetic Resonance Spectroscopy
5
Fulvestrant
5
Drug Therapy
5
Doxorubicin
5
Cisplatin
5
Biopsy
5
olaparib
4
lenvatinib
4
atezolizumab
4
Radiotherapy
4
Progestins
4
Observation
4
Nivolumab
4
Megestrol Acetate
4
Immunoglobulin G
4
Gemcitabine
4
trastuzumab deruxtecan
3
palbociclib
3
X-Rays
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Endometrial Neoplasms
×
Interleukin-2
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled